Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-confined Muscle-invasive Bladder Cancer

Urology

Volumn 102, Issue , 2017, Pages 148-158

  Chappidi, Meera R ^a   Kates, Max ^a   Brant, Aaron ^a   Baras, Alexander S ^a   Netto, George J ^a   Pierorazio, Phillip M ^a   Hahn, Noah M ^a   Bivalacqua, Trinity J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CYSTECTOMY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE INVASIVE BLADDER CANCER; NEOADJUVANT CHEMOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; BLADDER TUMOR; DISEASE EXACERBATION; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; SMOOTH MUSCLE; SURVIVAL RATE; TUMOR INVASION; VALIDATION STUDY;

AGED; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MUSCLE, SMOOTH; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 85010567570     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2016.10.064     Document Type: Article

References (30)

1. Grossman, H.B., Natale, R.B., Tangen, C.M., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349 (2003), 859–866.
2. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361 (2003), 1927–1934.
3. Advanced Bladder Cancer Overview Collaboration. Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev(2), 2005 CD005246.
4. Soloway, M.S., Selecting initial therapy for bladder cancer. Cancer 60:3 suppl (1987), 502–513.
5. Sternberg, C.N., de Mulder, P., Schornagel, J.H., et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42 (2006), 50–54.
6. Sonpavde, G., Goldman, B.H., Speights, V.O., et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 115 (2009), 4104–4109.
7. Gandhi, N.M., Baras, A., Munari, E., et al. Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: predicting response and assessing outcomes. Urol Oncol, 33, 2015, 204 e1-204.e7.
8. Scosyrev, E., Messing, E.M., van Wijngaarden, E., et al. Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer 118 (2012), 72–81.
9. Siefker-Radtke, A.O., Dinney, C.P., Shen, Y., et al. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Cancer 119 (2013), 540–547.
10. El-Gehani, F., North, S., Ghosh, S., Venner, P., Improving the outcome of patients with muscle invasive urothelial carcinoma of the bladder with neoadjuvant gemcitabine/cisplatin chemotherapy: a single institution experience. Can Urol Assoc J 8 (2014), e287–e293.
11. Sobin, L.H., Gospodarowicz, M.K., Wittekind, C., TNM classification of malignant tumors. 7th ed, 2009, John Wiley & Sons, Inc., Hoboken, NJ.
12. National Comprehensive Cancer Network Bladder Cancer Panel, NCCN clinical practice guidelines in oncology bladder cancer version 2. Available at: http://www.nccn.org/professionals/physician_gls/PDF/bladder.pdf, 2015 Updated 2015; Accessed December 10, 2015.
13. Mossanen, M., Lee, F., Cheng, H., et al. Nonresponse to neoadjuvant chemotherapy for muscle-invasive urothelial cell carcinoma of the bladder. Clin Genitourin Cancer 12 (2014), 210–213.
14. Shariat, S.F., Palapattu, G.S., Karakiewicz, P.I., et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 51 (2007), 137–149 discussion 149-51.
15. Turker, P., Bostrom, P.J., Wroclawski, M.L., et al. Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. BJU Int 110 (2012), 804–811.
16. NCDB, Getting started with the 2013 PUF. American College of Surgeons website; Available at: http://ncdbpuf.facs.org/node/274, 2000 Updated 2015; Accessed March 25, 2016.
17. Choueiri, T.K., Jacobus, S., Bellmunt, J., et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol 32 (2014), 1889–1894.
18. Hemdan, T., Malmstrom, P.U., Jahnson, S., Segersten, U., Emmprin expression predicts response and survival following cisplatin containing chemotherapy: a validation study in patients with bladder cancer from 2 randomized studies of cystectomy with and without neoadjuvant chemotherapy. J Urol 194 (2015), 1575–1581.
19. Plimack, E.R., Hoffman-Censits, J.H., Viterbo, R., et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol 32 (2014), 1895–1901.
20. McConkey, D.J., Choi, W., Shen, Y., et al. A prognostic gene expression signature in the molecular classification of chemotherapy-naive urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur Urol 69 (2016), 855–862.
21. Lerner, S.P., McConkey, D.J., Hoadley, K.A., et al. Bladder cancer molecular taxonomy: summary from a consensus meeting. Bl Cancer 2 (2016), 37–47.
22. Culp, S.H., Dickstein, R.J., Grossman, H.B., et al. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol 191 (2014), 40–47.
23. Dickstein, R.J., Kamat, A.M., Contemporary management of locally invasive bladder cancer. Oncology (Williston Park) 25 (2011), 1396–1405.
24. Rais-Bahrami, S., Pietryga, J.A., Nix, J.W., Contemporary role of advanced imaging for bladder cancer staging. Urol Oncol 34 (2015), 124–133.
25. Bostrom, P.J., van Rhijn, B.W.G., Fleshner, N.E., et al. Staging and staging errors in bladder cancer. Eur Urol Suppl., 9, 2010, 2.
26. Daneshmand, S., Ahmadi, H., Huynh, L.N., Dobos, N., Preoperative staging of invasive bladder cancer with dynamic gadolinium-enhanced magnetic resonance imaging: results from a prospective study. Urology 80 (2012), 1313–1318.
27. Giannarini, G., Petralia, G., Thoeny, H.C., Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature. Eur Urol 61 (2012), 326–340.
28. Dash, A., Pettus, J.A. 4th, Herr, H.W., et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer 113 (2008), 2471–2477.
29. Teramukai, S., Nishiyama, H., Matsui, Y., Ogawa, O., Fukushima, M., Evaluation for surrogacy of end points by using data from observational studies: tumor downstaging for evaluating neoadjuvant chemotherapy in invasive bladder cancer. Clin Cancer Res 12 (2006), 139–143.
30. Stein, J.P., Lieskovsky, G., Cote, R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19 (2001), 666–675.